Keratinocyte growth factor

Athar, Uzma; Gentile, Teresa

doi:10.1517/14712590902976837

Cited by 10 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Palifermin, a human recombinant keratinocyte growth factor has shown to reduce incidence, severity and duration of mucositis in phase III trials [178]. In tumor bearing DA rats’ single large dose of palifermin prior to CPT-11 administration was found to have delayed onset and reduced severity of diarrhea compared to all treatment groups.…”

Section: Strategies To Block Delayed Diarrheamentioning

confidence: 99%

Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis

Swami

Goel

Mani

2013

CDT

View full text Add to dashboard Cite

CPT-11 (irinotecan), a DNA topoisomerase I inhibitor is one of the main treatments for colorectal cancer. The main dose limiting toxicities are neutropenia and late onset diarrhea. Though neutropenia is manageable, CPT-11 induced diarrhea is frequently severe, resulting in hospitalizations, dose reductions or omissions leading to ineffective treatment administration. Many potential agents have been tested in preclinical and clinical studies to prevent or ameliorate CPT-11 induced late onset diarrhea. It is predicted that prophylaxis of CPT-11 induced diarrhea will reduce sub-therapeutic dosing as well as hospitalizations and will eventually lead to dose escalations resulting in better response rates. This article reviews various experimental agents and strategies employed to prevent this debilitating toxicity. Covered topics include schedule/dose modification, intestinal alkalization, structural/chemical modification, genetic testing, anti-diarrheal therapies, transporter (ABCB1, ABCC2, BCRP2) inhibitors, enzyme (β-glucuronidase, UGT1A1, CYP3A4, carboxylesterase, COX-2) inducers and inhibitors, probiotics, antibiotics, adsorbing agents, cytokine and growth factor activators and inhibitors and other miscellaneous agents.

show abstract

Section: Strategies To Block Delayed Diarrheamentioning

confidence: 99%

Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis

Swami

Goel

Mani

2013

CDT

View full text Add to dashboard Cite

show abstract

“…Some examples are worth mentioning. For example, no studies have extensively looked into the impact of biologic stimulation of mucosal recovery (for example, using recombinant human keratinocyte growth factor) 12 or of growth factors (for example, G-CSF) 13 on the risk of IFIs (mainly candidiasis) in the preengraftment period, even without antifungal prophylaxis. Similarly, few studies have systematically evaluated the impact of glucose control or treatment of iron overload 14 on the postengraftment period in patients in HSCT recipients with steroid-dependent GVHD.…”

Section: Introductionmentioning

confidence: 99%

Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success

Kontoyiannis

2010

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Fibrotic areas were counted on 200 random selected fields corresponding to approximately 6mm 2 , using an unbiased counting frame, as has been described previously [14]. The percentage of fibrotic area was expressed as a number of fibrotic fields divided by total fields, and then multiplied by 100.…”

Section: Evaluation Of Liver Fibrosismentioning

confidence: 99%

“…Thus, KGF acts predominantly in a paracrine manner. Importantly, KGF expression is strongly up-regulated after acute injury to various tissues, including skin, bladder, kidney and liver [14].…”

Section: Introductionmentioning

confidence: 99%

Suppression of MicroRNA-219-5p Activates Keratinocyte Growth Factor to Mitigate Severity of Experimental Cirrhosis

Chen

Cui²,

Feng³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Keratinocyte growth factor (KGF) plays a critical role in prevention of cirrhosis and enhancement of liver regeneration. However, the molecular regulation of KGF in liver is unknown. MicroRNAs (miRNAs) control the pathogenesis of cirrhosis, whereas the exact involved miRNAs and molecular signaling pathways remain ill-defined. Here we addressed these questions. Methods: We examined the correlation of the levels of miR-219-5p and KGF in the liver biopsies from patients with liver diseases. The effects of overexpression or suppression of miR-219-5p on KGF were examined in both human and mouse hepatic stellate cells (HSCs). Bioinformatics analysis was applied to examine the binding of human/mouse miR-219-5p to the 3'-UTR of human/mouse KGF mRNA, respectively. Finally, adeno-associated viruses carrying antisense of miR-219-5p were infused into the liver from the mice that had developed cirrhosis by carbon tetrachloride (CCl₄), and the effects on KGF levels and liver damage and function were examined. Results: The levels of miR-219-5p and KGF in the liver biopsies were inversely correlated. MiR-219-5p inhibited KGF expression in both human and mouse HSCs, through directly binding the 3'-UTR of KGF mRNA. Expression of antisense of miR-219-5p significantly attenuated the levels of liver fibrosis, portal hypertension and sodium retention caused by CCl₄. Conclusions: Suppression of miR-219-5p may benefit the liver regeneration and prevent cirrhosis through increasing KGF.

show abstract

Keratinocyte growth factor

Cited by 10 publications

References 39 publications

Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis

Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis

Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success

Suppression of MicroRNA-219-5p Activates Keratinocyte Growth Factor to Mitigate Severity of Experimental Cirrhosis

Contact Info

Product

Resources

About